Benitec

News Benitec

• uniQure licenses RNA interference technology to advance Huntington’s disease program

  uniQure B.V. announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec non-exclusive access to the Company’s AAV5 deliver more

• Benitec strengthenss Intellectual Property Position in Gene Silencing with more patents granted in Europe and the US

  Benitec Ltd announced that two further patents owned or licensed exclusively by Benitec have been granted or allowed in Europe and the US respectively.The CSIRO-owned patent EP1068311-B1 (“Methods and Means for Obtaining Modified Phenotypes”), for which Benitec is the exclusive licensee in the field more

• Benitec’s Hepatitis B RNAi Program with Biomics Biotechnologies Moves to the Next Stage Following Successful Stage 1 Results

  Benitec Limited announced that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement to more

Market studies Benitec

• RXi Pharmaceuticals Corporation (RXII) - Financial and Strategic SWOT Analysis Review

  RXi Pharmaceuticals Corporation (RXi) is a discovery-stage bio-pharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics based on RNA interference (RNAi) to treat human diseases. By using its RNAi platform that includes RNAi compounds and delivery meth more

• RNAi for Therapeutic Applications: Market Prospects 2011-2021

  How will the RNA interference (RNAi) therapies market develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021. You will see the commercial prospects for RNAi-based therapeutics. We aim to save you time and aid your decisions through our research, dat more

• bioMD Limited (BOD) - Financial and Strategic SWOT Analysis Review

  bioMD Limited (BOD) - Financial and Strategic SWOT Analysis Review Summary bioMD Limited (bioMD) is a Western Australia- based biomedical company that offers cost effective and safe medical devices and emerging medical and surgical technologies to the global healthcare market. It manufactures safe more

Websites Benitec